Inhibrx (Inhibrx) Purchase Of Investment : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Inhibrx Purchase Of Investment?

Inhibrx's purchase of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Inhibrx spent $0.00 Mil on purchasing investments. Inhibrx's purchase of investment for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Dec. 2023 ), Inhibrx spent the same money on purchasing investments in Mar. 2024 ($0.00 Mil).

Inhibrx Purchase Of Investment Historical Data

The historical data trend for Inhibrx's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx Purchase Of Investment Chart

Inhibrx Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Purchase Of Investment

Get a 7-Day Free Trial

Inhibrx Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Purchase Of Investment	Get a 7-Day Free Trial															-	-	-	-	-

Inhibrx Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Inhibrx Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of Inhibrx's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibrx (Inhibrx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Inc (NAS:INBX) » Definitions » Purchase Of Investment

Comparable Companies

Traded in Other Exchanges

N/A

Address

11025 N. Torrey Pines Road, Suite 200, La Jolla, CA, USA, 92037

Website

https://www.inhibrx.com

Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.

Executives

Ole Andreas Halvorsen	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc	10 percent owner	55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Mark Lappe	director, 10 percent owner, officer: Chief Executive Officer	11622 EL CAMINO REAL, SUITE 100, SAN DIEGO CA 92130
Brendan P. Eckelman	director, 10 percent owner, officer: Chief Scientific Officer	C/O INHIBRX, INC., 11025 N. TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jon Faiz Kayyem	director, 10 percent owner	5964 LA PLACE COURT, CARLSBAD CA 92008
Dragsa 50 Llc	10 percent owner	55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Portfolio Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Kristiina Md Vuori	director	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Klaus W. Wagner	officer: Chief Medical Officer	C/O INHIBRX, INC., 11025 N. TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Kimberly Manhard	director	C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121